Abstract:Recent global clinical trials have shown that CLDN18.2 is an ideal target for the treatment of gastric cancer and that patients with high CLDN18.2 expression can benefit from targeted therapy. Therefore, accurate and comprehensive detection of CLDN18.2 expression is important for patient screening and guidance in anti-CLDN18.2 therapy. Phage display technology was used to screen CLDN18.2-specific peptides from 100 billion libraries. 293TCLDN18.1 cells were used to exclude nonspecific binding and CLDN18.1 binding sequences, while 293TCLDN18.2 cells were used to screen CLDN18.2-specific binding peptides. The monoclonal clones obtained from phage screening were sequenced, and peptides were synthesized based on the sequencing results. Binding specificity and affinity were assessed with a fluorescein isothiocyanate (FITC)-conjugated peptide. A 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated peptide was also synthesized for 68Ga radiolabeling. The in vitro and in vivo stability, partition coefficients, in vivo molecular imaging, and biodistribution were also characterized. Overall, 54 monoclonal clones were selected after phage display screening. Subsequently, based on the cell ELISA results, CLDN18.2 preference monoclonal clones were selected for deoxyribonucleic acid (DNA) sequencing, and four 7-peptide sequences were obtained after sequence comparison; among them, a peptide named T37 was further validated in vitro and in vivo. The T37 peptide specifically recognized CLDN18.2 but not CLDN18.1 and bound strongly to CLDN18.2-positive cell membranes. The 68Ga-DOTA-T37 probe exhibits good in vitro properties and high stability as a hydrophilic probe; it has high biological safety, and positron emission tomography/computed tomography (PET/CT) studies have shown that it can specifically target CLDN18.2 protein and CLDN18.2-positive tumors in mice. 68Ga-DOTA-T37 demonstrated the superiority and feasibility of using a CLDN18.2-specific probe in PCT/CT imaging, which deserves further development and exploitation.

Screening of micromolecule polypeptide specific for bladder carcinoma cell T24

Screening and Identification of a Specific Peptide Binding to Hepatocellular Carcinoma Cells from a Phage Display Peptide Library

Identifying Peptides That Specifically Bind to MDA-MB-468 Breast Cancer Cells*

Screening and identification of a specific peptide binding to cervical cancer cells from a phage-displayed peptide library

Screening and identification of a specific peptide binding to breast cancer cells from a phage-displayed peptide library

Screening of a specific peptide binding to esophageal squamous carcinoma cells from phage displayed peptide library.

Novel Application of Cell Penetrating R11 Peptide for Diagnosis of Bladder Cancer

Tumor-Targeting Peptides Search Strategy for the Delivery of Therapeutic and Diagnostic Molecules to Tumor Cells

Screening, Construction, and Preliminary Evaluation of CLDN18.2-Specific Peptides for Noninvasive Molecular Imaging

Screening and Identification of a Specific Binding Peptide to Ovarian Cancer Cells from a Phage-Displayed Peptide Library

Immunoscreening of urinary bladder cancer cDNA library and identification of potential tumor antigen

Preclinical Study of Bladder Cancer Diagnosis Using Tumor Homing Peptide Fluorescent Molecular Probe

Screening and Identification of a Phage Display Derived Peptide That Specifically Binds to the CD44 Protein Region Encoded by Variable Exons.

THE FURTHER CHARACTERIZATION OF THE SPECIFICALLY BINDING PEPTIDE TO HEPATOCELLULAR CARCINOMA

Screening Tumor-Targeting Bacteriophage Particles by Pre-Clearing Phage Display

Identification of a peptide binding to cancer antigen Kita‐kyushu lung cancer antigen 1 from a phage‐display library

A clinical study of a CD44v6-targeted fluorescent agent for the detection of non-muscle invasive bladder cancer

Discovering of Tumor-Targeting Peptides Using Bi-Functional Microarray

Identification of a specific peptide binding to colon cancer cells from a phage-displayed peptide library

FL118: A potential bladder cancer therapeutic compound targeting H2A.X identified through library screening

A Study on Screening and Antitumor Effect of CD55-specific Ligand Peptide in Cervical Cancer Cells.